CLDX Q3 2018 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$941,000-76.0% YoY

Gross Profit

-$11M-1166.5% margin

Operating Income

-$8M-825.1% margin

Net Income

-$7M-769.7% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

-65.9%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$168M

Total Liabilities

$40M

Stockholders' Equity

$128M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$941,000	$4M	-76.0%
Gross Profit	-$11M	-$18M	+39.0%
Operating Income	-$8M	-$32M	+75.7%
Net Income	-$7M	-$26M	+72.5%

Revenue Segments

Contracts And Grants

$810,00086%

Product Development And Licensing Agreements

$131,00014%